Structures prenatal visit documentation with gestational age tracking, screening schedules, and risk assessment. Use when documenting prenatal visits, tracking pregnancy milestones, or managing prenatal screening.
Structures prenatal visit documentation with gestational age tracking, screening schedules, and risk assessment per ACOG guidelines.
Prenatal care is the cornerstone of obstetric practice, directly reducing maternal and neonatal morbidity. ACOG recommends a structured visit schedule — monthly through 28 weeks, biweekly from 28–36 weeks, and weekly from 36 weeks to delivery — with specific screenings at defined gestational windows. Missed screenings, inaccurate gestational dating, or unrecognized risk factors contribute to preventable adverse outcomes including preeclampsia, fetal growth restriction, and preterm birth.
Proper documentation ensures continuity across providers, supports medicolegal defensibility, and satisfies CMS prenatal bundled-payment requirements. This skill enforces the ACOG-recommended screening timeline and risk stratification framework so that every visit is captured with clinical precision.
Before drafting any prenatal documentation, confirm the following:
Accurate dating is the single most important element of prenatal care.
| Dating Method | Accuracy | When to Use |
|---|---|---|
| IVF transfer date | ± 1 day | Always use if available |
| CRL ultrasound < 9 weeks | ± 5 days | Preferred first-trimester method |
| CRL ultrasound 9–13+6 weeks | ± 7 days | Adjust EDD if discrepancy > 5 days from LMP |
| BPD/FL 14–15+6 weeks | ± 7 days | Adjust if discrepancy > 7 days from LMP |
| BPD/FL 16–21+6 weeks | ± 10 days | Adjust if discrepancy > 10 days from LMP |
| BPD/FL 22–27+6 weeks | ± 14 days | Adjust if discrepancy > 14 days from LMP |
| ≥ 28 weeks | ± 21 days | Do NOT change EDD based on third-trimester US |
Document the final agreed-upon EDD and the basis for dating. Once established, the EDD should not change.
Map each visit to its gestational-age-appropriate screenings:
| GA Window | Required Screenings |
|---|---|
| Initial visit | CBC, blood type/Rh/antibody screen, rubella, HBsAg, HIV, RPR, UA/UCx, Pap if due, chlamydia/gonorrhea |
| 10–13 weeks | First-trimester screen (PAPP-A, free β-hCG, NT), NIPT offered if desired |
| 15–20 weeks | Quad screen (if no first-trimester screen or NIPT), AFP for NTD screening |
| 18–22 weeks | Detailed anatomy ultrasound |
| 24–28 weeks | 1-hour GCT (50 g), Rh antibody screen if Rh-negative, RhoGAM administration |
| 28 weeks | Repeat CBC (anemia screen), Tdap vaccine |
| 35–37 weeks | GBS recto-vaginal culture |
| 36+ weeks | Cervical exam if indicated, fetal presentation assessment |
Flag any overdue screening with [OVERDUE — {test name} due at {GA}].
Categorize the patient at every visit using the ACOG risk-stratification model:
High-risk indicators requiring MFM referral or co-management:
Moderate-risk indicators requiring enhanced surveillance:
Document risk tier and any referrals initiated. Update risk status if new findings emerge.
Each prenatal visit note must include:
Weight gain targets per IOM guidelines:
| Pre-pregnancy BMI | Total Gain (lbs) | Rate 2nd/3rd Trimester (lbs/wk) |
|---|---|---|
| Underweight (< 18.5) | 28–40 | 1.0 |
| Normal (18.5–24.9) | 25–35 | 1.0 |
| Overweight (25–29.9) | 15–25 | 0.6 |
| Obese (≥ 30) | 11–20 | 0.5 |
Beginning at 36 weeks, document:
Before finalizing any prenatal care document, verify:
[OVERDUE] tags rather than silently omitting missed screenings.